BMRN (BioMarin Pharmaceutical) Ending Cash Position: $874 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMRN BioMarin Pharmaceutical Inc BMRN
81 GF Score
Price $66.99
GF Value $83.13
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Ending Cash Position?

BioMarin Pharmaceutical BMRN +0.53% 81 Ending Cash Position is $874 Mil as of Jun. 2026. GuruFocus rates BMRN with a GF Score™ of 81/100 and a GF Value™ of $83.13 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BioMarin Pharmaceutical's Ending Cash Position for the quarter that ended in Jun. 2026 was $874 Mil.

BioMarin Pharmaceutical's quarterly Ending Cash Position increased from Dec. 2025 ($1,312 Mil) to Mar. 2026 ($3,072 Mil) but then declined from Mar. 2026 ($3,072 Mil) to Jun. 2026 ($874 Mil).

BioMarin Pharmaceutical's annual Ending Cash Position increased from Dec. 2023 ($755 Mil) to Dec. 2024 ($943 Mil) and increased from Dec. 2024 ($943 Mil) to Dec. 2025 ($1,312 Mil).

BioMarin Pharmaceutical Ending Cash Position Related Terms

BioMarin Pharmaceutical Ending Cash Position Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Ending Cash Position Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 587.28 724.53 755.13 942.84 1,311.68

BioMarin Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,213.82 1,250.11 1,311.68 3,072.44 874.01
BMRN
81GF Score
BioMarin Pharmaceutical Inc BMRN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

BioMarin Pharmaceutical's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=942.842+368.837
=1,312

BioMarin Pharmaceutical's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3072.435+-2198.43
=874

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $874 Mil mean?
BioMarin Pharmaceutical (BMRN) has a Ending Cash Position of $874 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Ending Cash Position too high?
BioMarin Pharmaceutical's current Ending Cash Position is $874 Mil. Overall, BioMarin Pharmaceutical has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Ending Cash Position compare to TECH and CYTK?
BioMarin Pharmaceutical's Ending Cash Position of $874 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Ending Cash Position is $874 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.13, compared to a current price of $66.99 — trading 19.4% below its estimated fair value. The current Ending Cash Position is $874 Mil. BioMarin Pharmaceutical's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For BioMarin Pharmaceutical (BMRN), the current Ending Cash Position is $874 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of $66.99 is trading 19.4% below its estimated GF Value™ of $83.13. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for BMRN:

  • Ending Cash Position: $874 Mil
  • GF Value™: $83.13 vs. price of $66.99 (19.4% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
81GF Score

Get the complete analysis for BMRN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.99
Price
$83.13
GF Value